

Original Paper

Usage, Acceptability, and Effectiveness of an Activity Tracker in a Randomized Trial of a Workplace Sitting Intervention: Mixed-Methods Evaluation

Charlotte L Brakenridge¹, BPsySc (Hons); Genevieve N Healy^{1,2,3}, PhD; Elisabeth AH Winkler¹, PhD; Brianna S Fjeldsoe¹, PhD

¹School of Public Health, The University of Queensland, Brisbane, Australia

²Baker Heart and Diabetes Institute, Melbourne, Australia

³School of Physiotherapy and Exercise Science, Curtin University, Perth, Australia

Corresponding Author:

Charlotte L Brakenridge, BPsySc (Hons)

School of Public Health

The University of Queensland

Herston Rd

Brisbane, 4006

Australia

Phone: 61 733655163

Email: c.brakenridge@uq.edu.au

Abstract

Background: Wearable activity trackers are now a common feature of workplace wellness programs; however, their ability to impact sitting time (the behavior in which most of the desk-based workday is spent) is relatively unknown. This study evaluated the LUMObac, an activity tracker that targets sitting time, as part of a cluster-randomized workplace sitting intervention in desk-based office workers.

Objective: Study objectives were to explore: (1) office workers' self-directed LUMObac use, (2) individual-level characteristics associated with LUMObac use, (3) the impact of LUMObac use on activity and sitting behaviors, and (4) office workers' perceived LUMObac acceptability.

Methods: Exploratory analyses were conducted within the activity tracker intervention group (n=66) of a 2-arm cluster-randomized trial (n=153) with follow-up at 3 and 12 months. The intervention, delivered from within the workplace, consisted of organizational support strategies (eg, manager support, emails) to stand up, sit less, and move more, plus the provision of a LUMObac activity tracker. The LUMObac, worn belted around the waist, provides real-time sitting feedback through a mobile app. LUMObac usage data (n=62), Web-based questionnaires (n=33), activPAL-assessed sitting, prolonged (≥ 30 min bouts) and nonprolonged (< 30 min bouts) sitting, standing and stepping time (7-day, 24 h/day protocol; n=40), and telephone interviews (n=27) were used to evaluate study aims. LUMObac usage data were downloaded and described. Associations between user characteristics and LUMObac usage (in the first 3 months) were analyzed using zero-inflated negative binomial models. Associations between LUMObac usage and 3-month activity outcomes were analyzed using mixed models, correcting for cluster. LUMObac acceptability was explored using 3-month questionnaire data and thematic analysis of telephone interviews (conducted 6 to 10 months post intervention commencement).

Results: Tracker uptake was modest (43/61, 70%), and among users, usage over the first 3 months was low (1-48 days, median 8). Usage was greatest among team leaders and those with low self-perceived scores for job control and supervisor relationships. Greater tracker use (≥ 5 days vs < 5 days) was significantly associated only with changes in prolonged unbroken sitting (-50.7 min/16 h; 95% CI -94.0 to -7.3 ; $P=.02$) during all waking hours, and changes in nonprolonged sitting ($+32.5$ min/10 h; 95% CI 5.0 to 59.9 ; $P=.02$) during work hours. Participants found the LUMObac easy to use but only somewhat comfortable. Qualitatively, participants valued the real-time app feedback. Nonuptake was attributed to being busy and setup issues. Low usage was attributed to discomfort wearing the LUMObac.

Conclusions: The LUMObac—although able to reduce prolonged sitting time—was only used to a limited extent, and its low usage may provide a partial explanation for the limited behavior changes that occurred. Discomfort limited the feasibility of the

LUMObac for ongoing use. Such findings yield insight into how to improve upon implementing activity trackers in workplace settings.

(*Interact J Med Res* 2018;7(1):e5) doi: [10.2196/ijmr.9001](https://doi.org/10.2196/ijmr.9001)

KEYWORDS

wearable electronic devices; fitness trackers; sedentary lifestyle; exercise; workplace; adult

Introduction

Desk-based workers engage in high levels of sedentary time [1,2] (ie, waking behaviors spent in a sitting, reclining, or lying posture with low energy expenditure [3]), putting themselves at risk of musculoskeletal [4] and cardio-metabolic issues [5]. Much of this sitting time is in prolonged, unbroken bouts [1], which have additional cardio-metabolic risks compared with sitting with regular breaks [5]. Furthermore, desk-based workers spend only a small percentage of their workday stepping (<10% of work time) [2] and engage in minimal amounts of moderate to vigorous activity both in and outside of work hours [6]. Given that sedentary work is increasing [7] and workers spend the majority of their day at work [8], there is a need to design and evaluate interventions that target the desk-based workplace.

In recent years, consumer-based activity trackers have become a popular component of workplace wellness programs to increase workers' physical activity [9], and it is expected that by 2021, 171.9 million activity trackers will be in workplaces worldwide [10]. Most trackers offer features known to be important for behavior change including self-monitoring, real-time feedback and prompting, guided goal setting, and rich and tailored feedback data [11]. Their popular use in workplace wellness programs indicates that they may be a feasible and acceptable intervention strategy for organizations to disseminate [9], and there is emerging evidence to suggest that consumer-based activity trackers can improve physical activity outcomes in desk-based workers [12,13].

Despite these findings, investigation concerning how desk-based workers use consumer-based trackers, which worker characteristics are associated with use, and whether workers find trackers acceptable and appealing has been scarce. The limited evidence suggests that although initial engagement is high [12,13], use may drop off in the long term [13,14]. Tracker users have been shown to fall into distinct groups, with high use seen among young and fit adults, as well as older adults with a desire to improve their health [15]. Acceptability may depend on user motivation and ease of use of the tracker [14]. Furthermore, it is also unknown whether use of a consumer-based activity tracker that targets and provides real-time *sitting* feedback can result in reductions in desk-based workers' sitting time. Strategies that target increases in activity may not lead to reductions in sitting time [16], and therefore, trackers that specifically target sitting time need to be evaluated.

To address these gaps, this study explored the usage and acceptability of an activity tracker (the LUMObac) that provided real-time feedback on sitting among desk-based office workers participating in a cluster-randomized workplace trial, targeting reductions in prolonged sitting time [17,18]. The

LUMObac tracker was chosen over other activity trackers because it is one of the few commercially available trackers that specifically measures and provides real-time sitting feedback [19]. The aim of this study was to explore the following: (1) participants' LUMObac usage (ie, device wear); (2) which personal, health, job, and activity characteristics were associated with greater LUMObac usage; (3) the relationship between LUMObac usage and changes in sitting and activity outcomes both at work and across all waking hours; and (4) participants' acceptability and perceptions of the LUMObac.

Methods

Participants and Design

Details of the study [17] and the effectiveness outcomes [18] have been reported previously (trial registration: ACTRN12614000252617). Briefly, participants were desk-based office employees of a large international property and infrastructure group. Workers were recruited in teams from 2 locations (A and B). Teams were cluster-randomized to receive either organizational support strategies alone (Group ORG; 9 manager-led teams; 87 participants) or organizational support strategies plus the provision of a LUMObac tracker (Group ORG+Tracker; 9 manager-led teams; 66 participants). The intervention was ongoing; data collection occurred at baseline and 3 and 12 months post intervention commencement. Only the Group ORG+Tracker is examined in this study. The organizational support component, designed to be workplace driven, was delivered by a workplace champion (the organization's Head of Workplace Wellbeing) and consisted of an information booklet; emails with tips to stand up, sit less, and move more; and involvement of senior executives to support the study. Participants in both groups also received individualized feedback concerning their sitting time and physical activity as recorded by the activPAL after each assessment. The study was approved by the University of Queensland Behavioural and Social Sciences Ethical Review Committee (approval number: 2014000089). All participants provided written informed consent, which covered the 3-month evaluation, with reconsent required to participate in the 12-month evaluation [17].

The LUMObac Tracker

The activity tracker provided to participants was the LUMObac activity tracker (LUMO Bodytech, Mountain View, CA, USA). The LUMObac is worn as a belt around the lower back (over or under clothing) and provides real-time feedback (through a mobile app) on sitting, standing, sit-to-stand transitions, walking, running, step count, posture, and sleep. Users can set posture alerts that vibrate the belt when the user is in a poor lumbar posture (identified by pelvic tilt angle) and set sitting time push

notifications to their phone when sitting for periods of 15 min, 30 min, 45 min, 1 hour, or 2 hours (user-defined). The LUMObac provides valid and reliable measures of sitting time and number of steps [20,21].

LUMObac trackers, along with a 4-page instruction booklet, were distributed by the workplace champion in study week 1. Participants set up their LUMObacs in their own time but had the contact details of the project coordinator and the workplace champion for any questions. LUMObac setup required calibration to the user's sitting and standing posture, and this was guided through the app and booklet instructions. The LUMObac was originally designed as a posture rather than as a sitting device [19]. As such, the default settings of the tracker were to have vibrating alerts (based on posture) on and sitting notifications off. To be consistent with evaluating the use of the tracker as it would be used outside of the research context, these settings were not preadjusted by project staff; however, the booklet instructions indicated that both these settings could be changed by the participant if the participant wished. LUMObac data were downloaded by project staff and monitored for usage during the study period. No specific instruction was given to participants on how much to wear the LUMObac; however, participants who did not have any LUMObac usage data were followed up by the project coordinator (via email or phone) or by the workplace champion (in person) to troubleshoot issues about setup during weeks 3 to 10. Participants were permitted to keep the LUMObac after the study ended.

Data Collection

Usage data were collected from LUMO Bodytech every 2 weeks during the initial 3 months and periodically thereafter. Participants completed Web-based questionnaires (via LimeService, used to address aims 2 and 4) at baseline, 3 months, and 12 months. The questionnaires collected data on sociodemographics (baseline), health and job characteristics (baseline, 3 months, and 12 months), LUMObac acceptability (3 months), and usage of behavior change techniques (eg, goal setting and prompting) in the LUMObac app (3 and 12 months). Height and weight measurements were collected objectively in person at the baseline assessment or via self-report (used in aim 2). Sitting and activity data (used to address aims 2 and 3) were collected at baseline, 3 months, and 12 months via the activPAL3 activity monitor (PAL Technologies Ltd., Glasgow, Scotland, UK). Telephone interviews, conducted 6 to 10 months after intervention commencement, were used to collect qualitative data regarding the LUMObac's acceptability to participants (used to address aim 4). Because so few participants reconsented for the 12-month assessment, aims 2 and 3 consider only usage and outcomes over the first 3 months.

Measures

Personal, Health, and Job Characteristics

Key participant characteristics, as measured at baseline, were age, gender, highest level of education completed, job category (senior or team leader, managerial staff, other general staff), use of other activity-promoting apps and wearable devices (yes or no), confidence using a smartphone (1-5 scale, least to most

confidence), desired sitting at work ($\geq 50\%$, $< 50\%$ of work time) [22], knowledge of the health impacts of sitting (1-5 scale, least to most knowledge) [22], musculoskeletal symptoms (Nordic Musculoskeletal Questionnaire [23], categorized as problems over the last month [yes or no] in the upper body, back, and lower extremities), and physical and mental health-related quality of life (Short Form-12 version 1 [24], 0-100 scale) and several other health- and job-related scores, all measured on a 1-10 scale. Specifically, these were stress [25], job control [25], work satisfaction [25], supervisor relations [25] (all from the Health and Work Questionnaire), and job performance (self-rated job performance scale [26]). For all of the health- and job-related scores, apart from stress, higher values are desirable. Height and weight measurements were used to calculate body mass index at baseline.

Activity

Sitting and activity data were collected via the activPAL3 monitor. At each assessment, participants were asked to wear the monitor for 7 days, 24 hours per day. Further information on monitor processing has been provided in previous trial publications [17,18]. Activity outcomes considered here are time per 10 hours at work and time per 16 hours awake spent engaged in sitting, prolonged sitting (≥ 30 min continuously), nonprolonged sitting (< 30 min continuously), standing, and stepping. To take into account variations in work times between assessments, and between individuals, work hour outcomes were standardized to a 10-hour workday by multiplying by 10 hours and dividing by work wear time. Similarly, overall waking hour outcomes were standardized to a 16-hour day by multiplying by 16 hours and dividing by waking wear time. Work and waking times were collected by self-report.

LUMObac Usage

For participants who set up the LUMObac, data on LUMObac usage were downloaded as comma-separated value files from LUMO Bodytech. Each file contains date and time-stamped summaries per 5 min time interval on activity and posture in various metrics, and an indicator of whether the LUMObac was not worn or charging. Daily usage (hours/day) was estimated by calculating the time elapsed between the first and last 5-min time window each day during which the LUMObac recorded an activity other than lying down, and then subtracting from this usage time any probable device nonwear time (or sleep time) occurring during this period. Only days with ≥ 1 hour of usage were counted as days of usage. Participants with at least 1 day of usage were classed as LUMObac "users"; those with no days of usage, or who self-reported never using the LUMObac, were classed as "nonusers." Others who reported using the LUMObac but lacked usage data were classed as having an "unknown" degree of usage.

LUMObac usage over the initial 3 months of intervention was considered: continuously (days), as a binary classification (≥ 5 days or < 5 days), and as a 4-category classification (nonuser, limited user, infrequent user, or frequent user). The thresholds used for the 4-category classification were 0, 1-4, 5-15, and ≥ 16 days, respectively, over 3 months. Long-term (12-month) usage was also assessed for the subset of participants who had opted for the 12-month assessment. LUMObac usage during the

activity monitor assessment (yes or no) was also considered to provide some insight as to whether the timing of LUMObac wear (not just how much it was worn) was important for activity changes. Usage/nonusage during the activity monitor assessment was determined by the presence/absence of ≥ 1 day with ≥ 1 hour of usage over this time frame, or by self-report when LUMObac data were not available.

LUMObac Acceptability

All questionnaire items assessing LUMObac acceptability were created for the trial. Acceptability questionnaire items were closed response (1, not at all; 2, somewhat; 3, not sure; 4, comfortable/easy; and 5, extremely comfortable/easy) and assessed for the following: comfort of the LUMObac, the ease of setup of the LUMObac and app, ease of navigation and use of the app, and ease of LUMObac calibration to the user's posture. Participants' perceived usefulness of the LUMObac overall and of specific features such as the graphs, sitting notifications, and vibrating alerts were also assessed in closed-response items: 1, not at all; 2, somewhat; 3, not sure; 4, useful; 5, extremely useful; and, when relevant, 6, did not notice/use. Frequency of use of the behavior change features was also assessed (eg, "When wearing your LUMObac, how often did you have it set to vibrate?"), with response options from 1 (never) to 6 (all the time). The full list of questions is provided in Multimedia Appendix 1 of the study protocol [17].

All participants who had not withdrawn after the 3-month assessment were eligible to take part in the telephone interviews. To ensure representation across teams, it was planned that at least 2 participants per team would be interviewed, plus the team managers. Interviews continued until the data were saturated and at least 2 members per work team were interviewed, unless there were more than 5 unsuccessful attempts to interview. The lead author (CLB, in location B) conducted and recorded (using Audacity) one-on-one telephone interviews with participants (predominantly in location A), ranging in duration from 9 to 28 min (mean duration 14 min). These semi-structured interviews covered topics of general thoughts on the LUMObac, participant likes and dislikes, barriers to usage, use of the sitting notification, influence of work team on LUMObac use, and general activity tracker preferences.

Sample Size

The sample size was determined based on the needs of the cluster-randomized trial [17]. This study was exploratory and not powered on study aims. Minimum differences of interest (MDI) in this study were 30 min of sitting and standing and 15 min of stepping between LUMObac usage categories (\approx per 10 days of usage), and 2 days of LUMObac usage between groups (categorical variables), per amount of activity equivalent to the above, or per 1 standard deviation of other continuous variables.

Analysis

Statistical analyses were performed in STATA version ≥ 13 (StataCorp, College Station, TX, USA). Significance was set at $P < .05$ 2-tailed. Analyses were of all evaluable cases with missing or "unknown" data excluded. Mean and standard

deviation were reported for continuous variables, and percentage was reported for categorical variables.

To address aim 1, usage was described. In the case of non-normally distributed variables, the median and the 25th and 75th percentiles were reported in addition to the mean and SD. To address aim 2, associations of characteristics with LUMObac use (adjusting for age, sex, and location) were statistically tested using zero-inflated negative binomial models (which accounted for the excessive zeros, as indicated by the Vuong test). Results are reported as contrasts of marginal mean outcomes. To address aim 3, associations of LUMObac usage with activity outcomes were examined using linear mixed models, adjusting for baseline value of the outcome, age, and sex and correcting for team cluster. Models were checked for nonlinearity, non-normality of residuals, multicollinearity, heteroscedasticity, and influential cases. Outcomes were transformed when this improved models, with the results from these models presented back-transformed to regular units. Results are presented with and without influential cases, if these cases were found to change the interpretation of the results.

To address aim 4, acceptability of the LUMObac was described quantitatively, based on the questionnaire items, and qualitatively, based on thematic analysis of interview data. Qualitative interviews were transcribed verbatim using F4 software (audiotranscription, Marburg, Germany). Participant idiosyncrasies (eg, "um") were removed after transcription. Author CLB coded initial themes (using NVivo version 10 and Microsoft Office Word). These were then compared and contrasted with a second researcher and discussed and decided upon. Themes were not preidentified; however, some of the questions in the semi-structured interview had a narrow focus that heavily contributed to some of the themes. Themes were then compared and contrasted with the questionnaire data when these were available, with findings from both sources presented together.

Results

Participant Characteristics

Baseline characteristics of participants in the ORG+Tracker group (overall and by usage) are presented in [Multimedia Appendix 1](#). Participants (35 female and 31 male) on average were aged 37.6 (SD 7.8) years and engaged in high levels of sitting time during work hours (453.0 [SD 55.9] min/10 h, ie, 76% of work hours). The majority were university educated (54/63, 86%); either in managerial (38/66, 58%), team or senior leader (8/66, 12%), or general staff (20/66, 30%) positions; and confident to extremely confident using a smartphone (52/54, 96%).

Aim 1: LUMObac Uptake and Usage

Uptake

The LUMObac was provided to 61 participants. Overall, 5 participants did not receive the LUMObac because of either ineligibility (incompatible phone, not ambulatory, left organization; $n=3$) or refusal ($n=1$), or for an unknown reason ($n=1$; see [Multimedia Appendix 2](#) for flow diagram). Uptake

was modest overall (43/66, 65%) and within those provided a LUMObac (43/61, 70%). Nonusers' (n=18) reported reasons for nonuse were as follows: being too busy to set up (6/18, 33%), personal disruptions during the study period (4/18, 22%), having technical difficulties setting up (3/18, 17%), pregnancy (1/18, 6%), and unknown (4/18, 22%). An additional "user" was later classed as a nonuser as they only had a very small and invalid amount of usage data (<1 hour), bringing the total number of nonusers to 19. Nonusers of the LUMObac were less likely to provide 3-month follow-up activity data than LUMObac users (see [Multimedia Appendix 2](#)).


Short-Term Usage

Out of the remaining 42 users, 4 participants claimed to have used the LUMObac, but usage data could not be obtained from LUMO Bodytech. Among those whose usage data could be collected (n=38), the LUMObac was used over the first 3

months for 1 to 48 of a possible 91 days, with a mean of 11.7 (SD 11.8) days of use and median (25th, 75th percentile) of 8 (3, 15) days. As usage can be intermittent, the time from first to last recorded usage within the first 3 months was slightly longer than the days of usage, ranging from 1 to 78 days, with a mean of 24.5 (SD 21.3) days and median (25th, 75th percentile) of 17.5 (7, 38) days. Duration of usage on wear days averaged 9.8 (SD 3.7) h per day.

Figure 1 demonstrates the diverse patterns of usage during the first 3 months of the study by usage group. Only 9 participants (15%) were classed as frequent users, whereas the remaining participants were either infrequent users (16/62, 26%), limited users (13/62, 21%), or nonusers (24/62, 39%). Duration of usage on wear days (h/day) appeared to be longest in frequent users (mean 12.8, SD 1.6), followed by infrequent users (mean 10.0, SD 3.2), and then by limited users (mean 7.4, SD 3.8).

Figure 1. LUMObac use by study day over the first 3 months (91 days), ordered by first study day of use and total length of use within each usage category. Percentages do not add to 100% due to rounding.



Long-Term Usage

LUMObac usage after the 3-month assessment was evaluated in the 21 LUMObac users who consented to 12-month follow-up (reasons for nonconsent were not related to LUMObac usage; see [Multimedia Appendix 2](#)). Only 1 consenting participant used their LUMObac after the 3-month assessment, for 5 consecutive additional days in total, with the last day of use being day 185 (ie, approximately 6 months after intervention commencement).

Aim 2: Participant Characteristics Associated With Short-Term LUMObac Usage

Figure 2 shows the number of days of LUMObac use compared across personal, health, job, and activity characteristics. Job control and supervisor relations were the only statistically significant predictors of usage. For both variables, higher perceived scores were associated with fewer days of LUMObac usage (~3 days). Some of the nonsignificant differences were substantial (\geq the MDI). Specifically, being a senior or team leader rather than managerial staff was meaningfully associated with more days (~14 days) of LUMObac usage, whereas having higher perceived job performance, being a smoker, being overweight or obese, and having back or lower extremity musculoskeletal problems were meaningfully associated with fewer days (~2 to 4 days) of LUMObac usage. Other differences were small ($<$ the MDI).

Aim 3: Impact of Short-Term LUMObac Usage on Behavior Change

LUMObac usage for at least 5 days during the intervention period was significantly associated with more nonprolonged sitting time during work hours (+32.5 min/10 h workday, 95% CI 5.0 to 59.9, $P=.02$). An examination of Cook's distance (D) identified 2 influential cases (Cook's $D \geq .14$), and after removal of these cases, the association with nonprolonged sitting time was no longer statistically significant, although still tended in the same direction (+19.6 min/10 h, 95% CI -3.6 to 42.7, $P=.10$). Increases in nonprolonged sitting time were coupled with less prolonged sitting time (-38.1 min/10 h, 95% CI -80.1 to 3.9, $P=.08$), and only very small differences in sitting, standing, and stepping time changes during work hours (see [Table 1](#)).

During waking hours, those using the LUMObac for at least 5 days reduced their prolonged sitting time by significantly more than their lower usage counterparts (-50.7 min/16 h awake, 95% CI -94.0 to -7.3, $P=.02$). This comparatively greater shift in waking hours away from prolonged sitting time was coupled with a shift toward more nonprolonged sitting time (+25.4 min/16 h, 95% CI -5.7 to 56.6, $P=.11$), which became significant after the removal of 1 influential case (Cook's $D=.25$; +31.9 min/16 h, 95% CI 3.3 to 60.4, $P=.03$). In addition, there remained some small differences in sitting (-29.4 min/16 h, 95% CI -67.2 to 8.4, $P=.13$), standing (+21.1 min/16 h, 95% CI -10.7 to 52.9, $P=.19$), and stepping (+4.6 min/16 h, 95% CI -9.2 to 18.3, $P=.51$) changes, all favoring those who used the LUMObac for at least 5 days.

Figure 2. Predictors of number of days of LUMObac usage over the first 3 months (91 days) of the intervention. (Gray indicates personal characteristics, green indicates health characteristics, blue indicates job characteristics, orange indicates work activity characteristics, and red indicates overall activity characteristics. Boldface refers to difference \geq the minimum difference of interest. Marginal mean [95% CI] days of LUMObac use [zero inflated negative binomial models], adjusted for sex, age, and location contrasted between groups [categorical variables] or mean versus "mean + dose" [continuous variables]. Dose was 1 SD for most continuous variables, 6 min for sitting and standing, and 3 min for stepping, per day or workday. The CI for senior or team leader continues off figure.)




Table 1. Associations of LUMObac usage with 3-month activity changes during the intervention.

| Outcome | Used during the intervention for ≥ 5 days, yes vs no (adjusted mean difference, 95% CI) ^a | P value | Usage during activity assessment, yes vs no (adjusted mean difference, 95% CI) ^a | P value |
|---|---|---------|---|---------|
| Work hours, min/10 h workday^b | | | | |
| Sitting | −1.9 (−22.0 to 18.1) ^c | .85 | −7.5 (−27.8 to 12.9) ^c | .47 |
| Prolonged sitting | −38.1 (−80.1 to 3.9) | .08 | −28.3 (−74.0 to 17.4) | .23 |
| Nonprolonged sitting | 32.5 (5.0 to 59.9) | .02 | 24.7 (−8.0 to 57.4) | .14 |
| Standing | 0.7 (−17.3 to 18.7) | .94 | −1.5 (−18.8 to 15.7) | .86 |
| Stepping | 2.6 (−7.5 to 12.8) | .61 | 5.3 (−4.4 to 15.0) | .29 |
| All waking hours, min/16 h day^b | | | | |
| Sitting | −29.4 (−67.2 to 8.4) | .13 | −2.0 (−40.0 to 36.0) | .92 |
| Prolonged sitting | −50.7 (−94.0 to −7.3) | .02 | −35.1 (−79.4 to 9.2) | .12 |
| Nonprolonged sitting | 25.4 (−5.7 to 56.6) | .11 | 36.5 (7.5 to 65.6) | .01 |
| Standing | 21.1 (−10.7 to 52.9) | .19 | 4.2 (−27.1 to 35.5) | .79 |
| Stepping | 4.6 (−9.2 to 18.3) | .51 | −1.0 (−14.2 to 12.2) | .89 |

^aTable shows adjusted mean difference and 95% CI from linear mixed models, adjusting for baseline value of the outcome, age, and sex, and correcting for cluster. Italics indicate statistically significant association (set at $P < .05$ 2-tailed).

^bAnalyzes are of evaluable cases among the 66 ORG+Tracker participants, excluding those with missing activity outcomes at work ($n=30$), during waking hours ($n=26$), or with unknown usage during the intervention ($n=3$). Work hours analyses include 18 users and 15 nonusers during the intervention and 21 users and 15 nonusers during the assessment while waking hours analyses include 19 users and 18 nonusers during the intervention and 22 users and 18 nonusers during the assessment.

^cSitting time during work hours was modeled as natural log of (600 minutes minus sitting minutes); results are back-transformed to original units for presentation in the table.

Examining usage of the LUMObac specifically over the time frame that activity was being measured revealed that concurrent usage was significantly associated with more nonprolonged sitting time during waking hours (+36.5 min/16 h, 95% CI 7.5 to 65.6, $P=.01$) and, accordingly, less prolonged sitting time (−35.1 min/16 h, 95% CI −79.4 to 9.2, $P=.12$; which became significant after the removal of 2 influential [Cook's $D \geq 1.1$] cases: −42.0 min/16 h, 95% CI −81.4 to −2.6, $P=.04$). Otherwise, there were only very small differences in sitting, standing, and stepping time changes. The size of the observed differences in work hour activities were all small (<the MDI) in addition to not reaching statistical significance.

Aim 4: Acceptability and Perceptions of the LUMObac

At 3 months, questionnaire data were collected from 33 LUMObac users (13 male; aged 26–55 years; 4 team leaders, 1 senior leader, 15 managerial staff, and 13 general staff), and qualitative interviews were conducted with 22 LUMObac users (11 male; aged 26–57 years; 5 team leaders, 11 managerial staff, and 6 general staff) and 5 nonusers (3 male; aged 36–45 years; 1 team leader and 4 managerial staff). Several themes emerged from these 2 sources of data on LUMObac acceptability: (1) comfort of the LUMObac; (2) acceptability of the app, real-time feedback, and graphs; (3) use of the LUMObac features; (4) additional barriers; (5) perceived barriers in nonusers; (6) the perceived influence of others on LUMObac use; and (7) suggested improvements in an activity tracker. Supportive quotes are provided below and in [Multimedia Appendix 3](#).

Comfort of the LUMObac

A majority of survey respondents (21/33, 64%) reported the LUMObac as only being “somewhat comfortable,” 9 participants (27%) reported the LUMObac to be “not at all comfortable,” and only 3 participants (9%) reported the LUMObac to be “comfortable” (see [Multimedia Appendix 4](#)). Comfort was identified as an issue in the telephone interviews. Reported issues included being conscious of wearing the LUMObac, the waist placement, sweating when wearing it, and, for women in particular, being hard to wear with clothing.

I think it was something that was hard to wear with some types of clothes. Not something that you could just put on and not think about. It was certainly thought about all the time while you were wearing it.
[#3, female managerial staff, limited user]

Acceptability of the App, Real-Time Feedback, and Graphs

Most users perceived the LUMObac and app to be “easy” to “extremely easy” to set up ($n=22/33$, 67%), use and navigate (25/33, 76%; see [Multimedia Appendix 4](#)), and the feedback graphs to be at least “somewhat useful” for creating awareness of sitting, standing, stepping, and good posture behaviors (27/33 (82%), 27/33 (82%), 26/33 (79%), and 26/33 (79%), respectively; see [Multimedia Appendix 5](#)). In the interviews, many participants reported that it was informative to get the real-time feedback from the LUMObac app:

I liked that you could track your results and see how well you are doing, I think that was the most benefit

that you could constantly check where you're at. [#25, female general staff, infrequent user]

Use of the LUMObacK Features

Use of the sitting notification was modest, with half (16/33, 49%) not using it at all ([Multimedia Appendix 5](#)). Encouragingly though, most notification users (14/17, 82%) found the prompts to be at least “somewhat useful” for creating sitting awareness. Participants were most likely to select to be prompted for a sitting break every 30 min (11/17, 65%), compared with 15 min (2/17, 12%), 1 hour (3/17, 18%), or 2 hours (1/17, 6%).

The minimal use of the sitting notifications was echoed in the findings from the telephone interviews. When prompted, it appeared that not all participants were aware of the option to set sitting notifications or had forgotten. Out of those interviewees who did report using the sitting notification, some reported that the sitting notification was a “nice feature,” with one participant going on to say:

...[the sitting notification] actually became a useful conversation piece, you would be in a meeting and I would get a prompt and I'd stand up and I would explain to people what was going on, people thought it was interesting, so you are not just doing something weird like suddenly popping up in the middle of a meeting. [#21, male team leader, infrequent user]

However, other users reported that the notifications were annoying and they turned them off, or they were easy to ignore.

The vibrating posture alerts were widely used and were highly discussed by participants. Some participants found the vibrating alerts beneficial:

...just the intrusiveness of it was actually quite good because it was always front of mind, you kind of couldn't forget that it was there, especially when you had the pulse thing on. [#19, female managerial staff, limited user]

However, many participants found that the vibrating alerts were a key barrier to wear as they were annoying and/or caused distraction in meetings. Although some participants were happy once disabling the vibrating alerts, others felt the LUMObacK had lost its utility and purpose without the vibrations:

I did [turn the vibrating alerts off], but then I thought it's a bit pointless because, not doing anything. [#17, male general staff, infrequent user]

Additional Barriers

Some participants reported frustration having to repeatedly calibrate the LUMObacK so that it was correctly measuring activity and posture and providing correct prompting:

You needed to recalibrate it every now and then and it would buzz as a result or it would be buzzing when you are in a right position and it was just a bit annoying. [#20, male managerial staff, frequent user]

This was congruent with the questionnaire findings, with only just over half of participants (17/33, 52%) reporting the LUMObacK was easy to calibrate (see [Multimedia Appendix 4](#)). Forgetting to wear the LUMObacK was another barrier, with

some participants reporting that the monitor used for assessments (ie, the activPAL) was easier to wear because “it just sat there all the time” and they did not need to remember to take it off and put it on each day (as it was taped to their thigh). Other barriers reported by a small number of participants included not wanting to wear the LUMObacK at home because of the desire to sit and slouch and not be prompted during this time, having to charge the LUMObacK, and the LUMObacK app draining phone battery.

Perceived Barriers in Nonusers

Participants who did not wear the LUMObacK were also interviewed and elaborated on their perceived barriers to uptake. A small number of participants reported set-up or syncing issues with the LUMObacK. One of these participants mentioned that it would have been helpful having in-person assistance in setting up. A lack of interest, being too busy, or being forgetful also played a part for some participants not using the LUMObacK.

The Perceived Influence of Others on LUMObacK Use

Some participants reported that support from their team manager, the workplace champion, or other team members was related to uptake of the LUMObacK. However, a majority of participants reported that their LUMObacK use was not influenced by others because they did not talk about using the LUMObacK or they could not see if other team members were wearing it.

Suggested Improvements in an Activity Tracker

Participants were also asked about their suggested improvements in activity trackers. The key desires for trackers included (1) being comfortable to wear, (2) being discreet, (3) being easy to use, (4) being waterproof, and (5) providing a range of accurate data.

Something I could just leave on that I wouldn't need to take on and off all the time, something that is waterproof, something that is maybe not so visible. [#3, female managerial staff, limited user]

Discussion

Principal Findings

This is one of the first studies to comprehensively evaluate both the usage and acceptability of a wearable activity tracker when delivered as part of a workplace intervention. The real-time feedback was valuable to users, and greater use of the LUMObacK appeared to assist with reducing the amount of daily prolonged sitting during the intervention. However, only 70% (43/61) of participants provided with a LUMObacK used it. Among those who used the LUMObacK, the amount of usage (left to the participant's discretion) was very limited, with a median of 8 days of usage, and a maximum of 48 days of usage out of a possible 91 days. Being too busy, technology issues during setup, and a lack of interest were possible reasons for nonuse. Within users, comfort was a key reason for low usage of the LUMObacK. Having lower self-perceived job control and weaker supervisor relationships were significantly associated with more LUMObacK usage; while participants who were senior staff and team leaders, and participants with a better

health profile also tended to use the LUMObac more than their counterparts.

Workplace tracker interventions have previously seen high levels of tracker uptake (96-99%) [13,27]. However, in line with the findings observed in this study (where uptake was 70%), uptake of trackers when offered in real-world workplace wellness programs can be more modest (25-100%) [9]. In this study, some nonusers reported a lack of interest in their LUMObac tracker. Tracker use is a personal decision, and some workers simply may not want or need a device to track their behavior. As such, offering trackers to everyone is not necessarily going to be a catch-all solution, but just one of many strategies a workplace could offer its workers. Issues with setup of the device may also have impeded its uptake. Although the participants in this study felt confident using their smartphone, work demands and technological difficulties may have meant that in-person set-up support was still needed. This finding, in line with a previous study reporting technology barriers to tracker uptake [28], suggests that investing in additional support at the initiation stage may be warranted. Indeed, in one study where such support was provided (eg, downloading the app and setting up the tracker for the participant), uptake was 100% and usage was high across the study (median use of 95% days across 16 weeks of intervention) [29].

Even among those who proceeded to use the belt-worn LUMObac, usage was low. Workplace studies evaluating trackers clipped on to the hip or shoe [12,13,27], worn on the wrist [14,30], or worn in a range of hip, wrist, and chest locations [31] have reported usage ranging from a mean use of 79% days across 6 weeks of intervention [12] to a mean use of approximately 69% days across 3 months of intervention [27], and 15% to upward of 89% of participants still using their tracker after 2 months [13,14,30,31]. All studies reporting high usage incorporated monetary incentives [13,27] or text message/email prompts [12] to encourage usage. Usage in the studies without these additional features [14,30,31] was typically lower (15-60% of participants still using their tracker after 2 months). These findings suggest that additional strategies may be needed to achieve high tracker usage.

Social support strategies, such as being part of a team, sharing results with others, and participating in workplace competitions, may also be associated with increased uptake and use of activity trackers [9,32]. In this study, senior and team leaders tended to use the LUMObac more than other employees. Participants in these roles likely had a higher responsibility for managing health and safety issues, had more direct contact with the workplace champion (who was at a similar managerial level), and as such may have been more motivated to use their LUMObac tracker. Senior and team leader support facilitated LUMObac uptake for some participants, but they did not discuss ongoing LUMObac use with their teams. A greater extent of role modeling and discussion might be useful to promote tracker usage and could provide a means to alleviate issues with setup and calibration.

Greater users of the tracker tended to be healthier, which is consistent with previous research [15,33]. A novel finding was that participants with high self-perceived job control and

supervisor relationships used the LUMObac for significantly fewer days. It may have been that these participants felt more freedom and confidence in their work roles to discontinue use of the tracker. Participants who had musculoskeletal problems at baseline used the LUMObac for fewer days than those without problems. It is possible that minor back pain following the posture advice, which was reported by 3 participants in the adverse outcomes of the trial [18], was a reason for less use in those participants who already had musculoskeletal problems at baseline. The waist-worn belt may have also been particularly troublesome for those with pre-existing back problems.

Comfort of the LUMObac appeared to be a key contributor to the low overall usage identified in this study. Participants reported dislike of the belt placement, and some noted that the LUMObac was difficult to wear with clothing. Similar findings have been reported with the Actigraph GT3X+ when attached via a belt [34] and for trackers worn tightly secured to the body [31]. Alternatives to belts, such as wristbands and clips, may be especially useful for long-term use with office clothing. However, the wrist and hip wear positions suited to wristbands and clips are not ideal for measuring sitting time [20] as they can lead to standing being misidentified as sitting. Other barriers identified by participants in this study and across other tracker research include a lack of perceived data accuracy, forgetting to use or charge the tracker, and difficulty using the tracker [14,30,31]. These findings suggest that, even with additional support, trackers need to be comfortable, accurate, discreet, and easy to use to facilitate ongoing use.

Consistent with other workplace tracker studies [14,31], we saw very limited usage of the LUMObac after 3 months (ie, only 1 out of the 21 participants whom we could follow up). However, the need for continuous self-monitoring of behavior is debatable [35]. Disuse of a tracker after a short period could indicate that participants have learned about their behavior and made changes rather than indicating failure to change [31]. Alternatively, the intermittent usage observed for some participants may reflect that self-monitoring provides a way to reidentify and adjust behavior as needed. Our findings did not suggest that the behavioral impact of the LUMObac is limited to the time frame over which it was worn; usage during the activity monitoring did not appear to predict behavior change any better than usage over the intervention generally, much of which occurred early on. A period of initial tracking may be sufficient to facilitate 3-month behavior changes. However, further research is needed to understand the interplay between tracker use and behavior.

Encouragingly, even within a group who used the LUMObac to a limited degree, larger favorable behavior changes during the intervention were seen in those with high usage compared with those with low or no usage. Greater usage during the intervention was significantly associated with overall time per day spent in prolonged sitting and, although there should be caution in interpreting this result, time spent in nonprolonged sitting during work hours. Unlike the majority of commercially available activity trackers [20], the LUMObac used posture measurement to detect and prompt on sitting time, which may be why this particular tracker was able to facilitate improvements in prolonged sitting time during the intervention.

However, the LUMObac is no longer commercially available. Thus, it is recommended that current and future commercial activity trackers include features to distinguish between sitting and upright postures so that they can appropriately measure and prompt on sitting time.

Notably, use of the LUMObac was not significantly associated with changes in sitting, standing, and stepping time. Greater changes in these behaviors may require greater use of the LUMObac and/or additional behavioral strategies. Environmental modifications to the workplace (eg, sit-stand workstations) and/or changes to the design of work tasks (eg, activity-based working, where workers can change workspace depending on work task) may also be needed to support regular shifts between sitting, standing, and moving.

Strengths and Limitations

A key study strength was that use of the LUMObac was self-directed by the participant and was provided as part of a broader workplace program. Thus, the findings are likely to be indicative of how a tracker may be implemented and used as part of a real-world worksite-driven program. The evaluation over the longer term enabled the examination of how the LUMObac was being used over time (and by whom), whereas the qualitative investigation added depth to the findings by exploring the reasons for lack of uptake and ceased use. It is recommended that future tracker evaluations take this mixed-methods approach.

This study was not powered a priori on the aims of this paper. Confidence intervals around estimates indicated that substantial differences in sociodemographic and health- and job-related predictors of usage and substantial differences in activity changes by usage may have been missed due to inadequate precision. Moreover, the limited differences in activity changes by usage may in part be due to a mismatch between when

participants used their LUMObac and when we captured their behavior. Evaluating usage and behavior over a more similar time frame (the assessment period vs the intervention) did not tend to strengthen associations; however, our examination would not detect very short-term effects of usage on behavior (eg, on the same day or at the same time). This may be an important question to address in a sample with sufficient usage. Biases may have had an impact on the results. Due to the small sample size, it was not possible to adjust for all potential confounders. Information was not collected on those who declined participation or who were never approached. LUMObac nonusers were also more likely to drop out of the study than LUMObac users. This attrition bias suggests our results, if anything, are likely to underestimate the associations of usage with behavior change. Although only some participants participated in the telephone interviews, interviews were conducted in both LUMObac users and nonusers, and a range of perspectives was collected. Generalizability is limited to the type of tracker used (belt-worn tracker focused on posture and sitting) and to the context of its use. Notably, it was allocated and provided by others (not chosen or purchased by the user) in the context of a team-based workplace-delivered organizational intervention. Use of a tracker that is self-selected by participants might lead to greater uptake and/or longer usage. Self-selection may especially encourage usage in those with high job control who may be accustomed to having a high level of autonomy in their working life.

Conclusions

A tracker that provides real-time feedback on sitting time was associated with the reduction of prolonged sitting time during a workplace-delivered sitting-reduction intervention. The tracker evaluated was not particularly suitable for ongoing use in office workers, but this study has provided insight into barriers and facilitators for uptake and ongoing tracker use in this population.

Acknowledgments

This work was supported by a Vanguard Grant (Award ID: 100216) from the National Heart Foundation of Australia, a grant from the Office Ergonomics Research Committee, and Lendlease. The National Health and Medical Research Council (NHMRC) of Australia, through a Centre of Research Excellence Grant (#1057608) to GNH, provides salary support to EAHW and a top-up scholarship to CLB. CLB is also supported by an Australian Government Research Training Program Scholarship. GNH is supported by a NHMRC Career Development Fellowship (#108029). The authors would like to thank Lendlease staff for their participation in the study.

Authors' Contributions

CLB participated in the design, led the coordination and data collection of the study, conducted all analyses, and drafted the manuscript. GNH participated in the design of the study and helped draft the manuscript. EAHW and BSF participated in the design of the study, assisted in the analyses, and helped draft the manuscript. All authors contributed to, read, and approved the final manuscript.

Conflicts of Interest

None declared.

Multimedia Appendix 1

Characteristics of participants randomized to the ORG+Tracker intervention overall and by usage group.

[\[PDF File \(Adobe PDF File\), 42KB-Multimedia Appendix 1\]](#)

Multimedia Appendix 2

Participant flow diagram.

[[PDF File \(Adobe PDF File\), 83KB-Multimedia Appendix 2](#)]

Multimedia Appendix 3

Additional participant quotes.

[[PDF File \(Adobe PDF File\), 27KB-Multimedia Appendix 3](#)]

Multimedia Appendix 4

Acceptability of the LUMOback.

[[PDF File \(Adobe PDF File\), 23KB-Multimedia Appendix 4](#)]

Multimedia Appendix 5

Use and perceived usefulness of the LUMOback features.

[[PDF File \(Adobe PDF File\), 23KB-Multimedia Appendix 5](#)]

References

1. Ryan CG, Dall PM, Granat MH, Grant PM. Sitting patterns at work: objective measurement of adherence to current recommendations. *Ergonomics*. Jun 2011;54(6):531-538. [doi: [10.1080/00140139.2011.570458](#)]
2. Healy GN, Eakin EG, Owen N, Lamontagne AD, Moodie M, Winkler EA, et al. A cluster randomized controlled trial to reduce office workers' sitting time: effect on activity outcomes. *Med Sci Sports Exerc*. Sep 2016;48(9):1787-1797. [doi: [10.1249/MSS.0000000000000972](#)] [Medline: [27526175](#)]
3. Tremblay MS, Aubert S, Barnes JD, Saunders TJ, Carson V, Latimer-Cheung AE, et al. SBRN Terminology Consensus Project Participants. Sedentary Behavior Research Network (SBRN) - terminology consensus project process and outcome. *Int J Behav Nutr Phys Act*. Jun 10, 2017;14(1):75. [FREE Full text] [doi: [10.1186/s12966-017-0525-8](#)] [Medline: [28599680](#)]
4. Ariëns GA, van Mechelen W, Bongers PM, Bouter LM, van der Wal G. Physical risk factors for neck pain. *Scand J Work Environ Health*. Feb 2000;26(1):7-19. [FREE Full text] [Medline: [10744172](#)]
5. Healy GN, Matthews CE, Dunstan DW, Winkler EA, Owen N. Sedentary time and cardio-metabolic biomarkers in US adults: NHANES 2003-06. *Eur Heart J*. Mar 2011;32(5):590-597. [FREE Full text] [doi: [10.1093/eurheartj/ehq451](#)] [Medline: [21224291](#)]
6. Clemes SA, O'Connell SE, Edwardson CL. Office workers' objectively measured sedentary behavior and physical activity during and outside working hours. *J Occup Environ Med*. Mar 2014;56(3):298-303. [doi: [10.1097/JOM.0000000000000101](#)] [Medline: [24603203](#)]
7. Church TS, Thomas DM, Tudor-Locke C, Katzmarzyk PT, Earnest CP, Rodarte RQ, et al. Trends over 5 decades in U.S. occupation-related physical activity and their associations with obesity. *PLoS One*. 2011;6(5):e19657. [FREE Full text] [doi: [10.1371/journal.pone.0019657](#)] [Medline: [21647427](#)]
8. U.S. Bureau of Labor Statistics. URL: <http://www.bls.gov/tus/charts/> [WebCite Cache ID 6xDp6Wyto]
9. Health Enhancement Research Organization. URL: <http://hero-health.org/wp-content/uploads/2015/06/HERO-Wearables-in-Wellness-Report-FINAL.pdf> [WebCite Cache ID 6xDpE5tX1]
10. Tractica. URL: <https://www.tractica.com/newsroom/press-releases/more-than-66-million-wearable-devices-will-be-shipped-annually-for-use-in-enterprise-and-industrial-environments-by-2021/> [accessed 2017-02-09] [WebCite Cache ID 6xDpT0UNC]
11. Lyons EJ, Lewis ZH, Mayrsohn BG, Rowland JL. Behavior change techniques implemented in electronic lifestyle activity monitors: a systematic content analysis. *J Med Internet Res*. 2014;16(8):e192. [FREE Full text] [doi: [10.2196/jmir.3469](#)] [Medline: [25131661](#)]
12. Poirier J, Bennett WL, Jerome GJ, Shah NG, Lazo M, Yeh H, et al. Effectiveness of an activity tracker- and internet-based adaptive walking program for adults: a randomized controlled trial. *J Med Internet Res*. 2016;18(2):e34. [FREE Full text] [doi: [10.2196/jmir.5295](#)] [Medline: [26860434](#)]
13. Finkelstein EA, Haaland BA, Bilger M, Sahasranaman A, Sloan RA, Nang EE, et al. Effectiveness of activity trackers with and without incentives to increase physical activity (TRIPPA): a randomised controlled trial. *Lancet Diabetes Endocrinol*. Dec 2016;4(12):983-995. [doi: [10.1016/S2213-8587\(16\)30284-4](#)] [Medline: [27717766](#)]
14. Boulard Masson C, Martin D, Colombino T, Grasso A. "The device is not well designed for me" on the use of activity trackers in the workplace? Cham, Switzerland. Springer; 2016. Presented at: COOP 2016 the 12th International Conference on the Design of Cooperative Systems; May 23-27, 2016;39-55; Trento, Italy.

15. Ledger D, McCaffrey D. Endeavour. 2014. URL: <https://blog.endeavour.partners/inside-wearable-how-the-science-of-human-behavior-change-offers-the-secret-to-long-term-engagement-a15b3c7d4cf3?gi=db661960715> [accessed 2018-02-19] [WebCite Cache ID 6xMd2fmTS]
16. Martin A, Fitzsimons C, Jepson R, Saunders DH, van der Ploeg HP, Teixeira PJ, et al. EuroFIT consortium. Interventions with potential to reduce sedentary time in adults: systematic review and meta-analysis. *Br J Sports Med*. Aug 2015;49(16):1056-1063. [doi: [10.1136/bjsports-2014-094524](https://doi.org/10.1136/bjsports-2014-094524)] [Medline: [25907181](https://pubmed.ncbi.nlm.nih.gov/25907181/)]
17. Brakenridge CL, Fjeldsoe BS, Young DC, Winkler EA, Dunstan DW, Straker LM, et al. Organizational-level strategies with or without an activity tracker to reduce office workers' sitting time: rationale and study design of a pilot cluster-randomized trial. *JMIR Res Protoc*. May 25, 2016;5(2):e73. [FREE Full text] [doi: [10.2196/resprot.5438](https://doi.org/10.2196/resprot.5438)] [Medline: [27226457](https://pubmed.ncbi.nlm.nih.gov/27226457/)]
18. Brakenridge CL, Fjeldsoe BS, Young DC, Winkler EA, Dunstan DW, Straker LM, et al. Evaluating the effectiveness of organisational-level strategies with or without an activity tracker to reduce office workers' sitting time: a cluster-randomised trial. *Int J Behav Nutr Phys Act*. Nov 04, 2016;13(1):115. [FREE Full text] [doi: [10.1186/s12966-016-0441-3](https://doi.org/10.1186/s12966-016-0441-3)] [Medline: [27814738](https://pubmed.ncbi.nlm.nih.gov/27814738/)]
19. Sanders JP, Loveday A, Pearson N, Edwardson C, Yates T, Biddle SJ, et al. Devices for self-monitoring sedentary time or physical activity: a scoping review. *J Med Internet Res*. May 04, 2016;18(5):e90. [FREE Full text] [doi: [10.2196/jmir.5373](https://doi.org/10.2196/jmir.5373)] [Medline: [27145905](https://pubmed.ncbi.nlm.nih.gov/27145905/)]
20. Rosenberger ME, Buman MP, Haskell WL, McConnell MV, Carstensen LL. 24 hours of sleep, sedentary behavior, and physical activity with nine wearable devices. *Med Sci Sports Exerc*. Mar 2016;48(3):457-465. [doi: [10.1249/MSS.0000000000000778](https://doi.org/10.1249/MSS.0000000000000778)] [Medline: [26484953](https://pubmed.ncbi.nlm.nih.gov/26484953/)]
21. Kooiman TJ, Dontje ML, Sprenger SR, Krijnen WP, van der Schans CP, de Groot M. Reliability and validity of ten consumer activity trackers. *BMC Sports Sci Med Rehabil*. 2015;7:24. [FREE Full text] [doi: [10.1186/s13102-015-0018-5](https://doi.org/10.1186/s13102-015-0018-5)] [Medline: [26464801](https://pubmed.ncbi.nlm.nih.gov/26464801/)]
22. Dunstan DW, Wiesner G, Eakin EG, Neuhaus M, Owen N, LaMontagne AD, et al. Reducing office workers' sitting time: rationale and study design for the Stand Up Victoria cluster randomized trial. *BMC Public Health*. 2013;13:1057. [FREE Full text] [doi: [10.1186/1471-2458-13-1057](https://doi.org/10.1186/1471-2458-13-1057)] [Medline: [24209423](https://pubmed.ncbi.nlm.nih.gov/24209423/)]
23. Kuorinka I, Jonsson B, Kilbom A, Vinterberg H, Biering-Sørensen F, Andersson G, et al. Standardised nordic questionnaires for the analysis of musculoskeletal symptoms. *Appl Ergon*. Sep 1987;18(3):233-237. [Medline: [15676628](https://pubmed.ncbi.nlm.nih.gov/15676628/)]
24. Ware J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. *Med Care*. Mar 1996;34(3):220-233. [Medline: [8628042](https://pubmed.ncbi.nlm.nih.gov/8628042/)]
25. Shikar R, Halpern MT, Rentz AM, Khan ZM. Development of the Health and Work Questionnaire (HWQ): an instrument for assessing workplace productivity in relation to worker health. *Work*. 2004;22(3):219-229. [Medline: [15156087](https://pubmed.ncbi.nlm.nih.gov/15156087/)]
26. Sundstrom E, Town JP, Rice RW, Osborn DP, Brill M. Office noise, satisfaction, and performance. *Environ Behav*. Mar 1994;26(2):195-222. [doi: [10.1177/001391659402600204](https://doi.org/10.1177/001391659402600204)]
27. Thorndike AN, Mills S, Sonnenberg L, Palakshappa D, Gao T, Pau CT, et al. Activity monitor intervention to promote physical activity of physicians-in-training: randomized controlled trial. *PLoS One*. 2014;9(6):e100251. [FREE Full text] [doi: [10.1371/journal.pone.0100251](https://doi.org/10.1371/journal.pone.0100251)] [Medline: [24950218](https://pubmed.ncbi.nlm.nih.gov/24950218/)]
28. Gilson ND, Pavey TG, Vandelanotte C, Duncan MJ, Gomersall SR, Trost SG, et al. Chronic disease risks and use of a smartphone application during a physical activity and dietary intervention in Australian truck drivers. *Aust N Z J Public Health*. Feb 2016;40(1):91-93. [doi: [10.1111/1753-6405.12501](https://doi.org/10.1111/1753-6405.12501)] [Medline: [26713400](https://pubmed.ncbi.nlm.nih.gov/26713400/)]
29. Cadmus-Bertram L, Marcus BH, Patterson RE, Parker BA, Morey BL. Use of the fitbit to measure adherence to a physical activity intervention among overweight or obese, postmenopausal women: self-monitoring trajectory during 16 weeks. *JMIR Mhealth Uhealth*. 2015;3(4):e96. [FREE Full text] [doi: [10.2196/mhealth.4229](https://doi.org/10.2196/mhealth.4229)] [Medline: [26586418](https://pubmed.ncbi.nlm.nih.gov/26586418/)]
30. Schrager JD, Shayne P, Wolf S, Das S, Patzer RE, White M, et al. Assessing the influence of a fitbit physical activity monitor on the exercise practices of emergency medicine residents: a pilot study. *JMIR Mhealth Uhealth*. Jan 31, 2017;5(1):e2. [FREE Full text] [doi: [10.2196/mhealth.6239](https://doi.org/10.2196/mhealth.6239)] [Medline: [28143805](https://pubmed.ncbi.nlm.nih.gov/28143805/)]
31. Lazar A, Koehler C, Tanenbaum J, Nguyen DH. Why we use and abandon smart devices. ACM. 2015. Presented at: UbiComp '15 the 2015 ACM International Joint Conference on Pervasive Ubiquitous Computing; September 7-11, 2015; Osaka, Japan.
32. Harrison D, Marshall P, Bianchi-Berthouze N, Bird J. Activity tracking: barriers, workarounds and customisation. ACM. 2015. Presented at: UbiComp '15 the 2015 ACM International Joint Conference on Pervasive Ubiquitous Computing; September 7-11, 2015; Osaka, Japan.
33. Yingling LR, Mitchell V, Ayers CR, Peters-Lawrence M, Wallen GR, Brooks AT, et al. Adherence with physical activity monitoring wearable devices in a community-based population: observations from the Washington, D.C., Cardiovascular Health and Needs Assessment. *Transl Behav Med*. Dec 2017;7(4):719-730. [FREE Full text] [doi: [10.1007/s13142-016-0454-0](https://doi.org/10.1007/s13142-016-0454-0)] [Medline: [28097627](https://pubmed.ncbi.nlm.nih.gov/28097627/)]
34. Huberty J, Ehlers DK, Kurka J, Ainsworth B, Buman M. Feasibility of three wearable sensors for 24 hour monitoring in middle-aged women. *BMC Womens Health*. Jul 30, 2015;15:55. [FREE Full text] [doi: [10.1186/s12905-015-0212-3](https://doi.org/10.1186/s12905-015-0212-3)] [Medline: [26223521](https://pubmed.ncbi.nlm.nih.gov/26223521/)]

35. Fjeldsoe B, Neuhaus M, Winkler E, Eakin E. Systematic review of maintenance of behavior change following physical activity and dietary interventions. *Health Psychol.* Jan 2011;30(1):99-109. [doi: [10.1037/a0021974](https://doi.org/10.1037/a0021974)] [Medline: [21299298](https://pubmed.ncbi.nlm.nih.gov/21299298/)]

Abbreviations

MDI: minimum difference of interest

Edited by TR Soron; submitted 20.09.17; peer-reviewed by M Whelan, D Ummels, J Di; comments to author 11.10.17; revised version received 06.12.17; accepted 21.12.17; published 02.03.18

Please cite as:

Brakenridge CL, Healy GN, Winkler EAH, Fjeldsoe BS

Usage, Acceptability, and Effectiveness of an Activity Tracker in a Randomized Trial of a Workplace Sitting Intervention: Mixed-Methods Evaluation

Interact J Med Res 2018;7(1):e5

URL: <http://www.i-jmr.org/2018/1/e5/>

doi: [10.2196/ijmr.9001](https://doi.org/10.2196/ijmr.9001)

PMID: [29500158](https://pubmed.ncbi.nlm.nih.gov/29500158/)

©Charlotte L Brakenridge, Genevieve N Healy, Elisabeth AH Winkler, Brianna S Fjeldsoe. Originally published in the Interactive Journal of Medical Research (<http://www.i-jmr.org/>), 02.03.2018. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Interactive Journal of Medical Research, is properly cited. The complete bibliographic information, a link to the original publication on <http://www.i-jmr.org/>, as well as this copyright and license information must be included.